• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA SYR(3*2ML); ACID, HYALURONIC, INTRAARTICULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA SYR(3*2ML); ACID, HYALURONIC, INTRAARTICULAR Back to Search Results
Lot Number V18654A
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Type  malfunction  
Event Description
Spontaneous report.Healthcare provider from doctor's office called in to report defective euflexxa syringe.She reported one of the syringes was defective and the other two were usable.She reported the syringe was cracked and medication may have spilled out.Patient was able to complete first two weeks of injections but missed the third.No adverse event reported.Unknown if defective product available for return.No additional information provided.Indication: unilateral primary osteoarthritis, unspecified knee.Reported to cvs/caremark by health professional.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Type of Device
ACID, HYALURONIC, INTRAARTICULAR
Manufacturer (Section D)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
MDR Report Key18994176
MDR Text Key338937055
Report NumberMW5153324
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 03/26/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Lot NumberV18654A
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received Not provided
Initial Date FDA Received03/27/2024
Patient Sequence Number1
Patient SexFemale
-
-